nach oben

Breast Cancer Research and Treatment

Erschienen in:

01.12.2014 | Clinical trial

Association between rim enhancement of breast cancer on dynamic contrast-enhanced MRI and patient outcome: impact of subtype

verfasst von: Alexander M. Th. Schmitz, Claudette E. Loo, Jelle Wesseling, Ruud M. Pijnappel, Kenneth G. A. Gilhuijs

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

The heterogeneous nature of breast cancer is represented by three breast cancer subtypes associated with different patient outcome. However, within subtypes, variations still exist. Additional stratification is necessary for more individualized therapy. Functional tumor characteristics on dynamic contrast-enhanced (DCE)-MRI may play a role. Rim enhancement of breast cancers has been associated with unfavorable pathology characteristics in the context of outcome. However, existence of a direct link is unknown. The purpose was to retrospectively determine the association between rim enhancement on DCE-MRI and long-term patient outcome, and whether it has complementary value to subtype. Preoperative DCE-MRI was performed in 556 consecutive female patients who were eligible for breast-conserving therapy. Presence of rim enhancement was assessed. Tumor characteristics were derived from resection specimens. Patients were stratified according to subtype. Association was assessed between rim enhancement and patient, pathology and treatment characteristics, recurrence-free interval and invasive disease-free survival. Median follow-up was 84 months. Patients were stratified into ER-positive/HER2-negative (N = 416), HER2-positive (N = 75), or triple-negative (N = 65) subtypes. Rim enhancement was seen in 29.0 % (N = 161/556) of tumors and was associated with higher histologic grade, negative ER-status, and triple-negative subtype. Only within triple-negative tumors, an association was seen with outcome. Recurrence was lower in non-rim-enhancing tumors (N = 1/36; 2.8 %) compared to rim-enhancing tumors (N = 9/28; 32.1 %) (p = 0.001). Survival was higher in non-rim-enhancing tumors (N = 34/36; 94.4 %) compared to rim-enhancing tumors (N = 18/28; 64.3 %) (p = 0.001). Rim enhancement on DCE-MRI is associated with long-term outcome of patients with triple-negative breast cancer and may potentially serve as a prognostic biomarker in these patients.

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRef

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874PubMedCentralPubMedCrossRef

Szabo BK, Aspelin P, Kristoffersen WM, Tot T, Bone B (2003) Invasive breast cancer: correlation of dynamic MR features with prognostic factors. Eur Radiol 13:2425–2435PubMedCrossRef

Chang YW, Kwon KH, Choi DL, Lee DW, Lee MH et al (2009) Magnetic resonance imaging of breast cancer and correlation with prognostic factors. Acta Radiol 50:990–998PubMedCrossRef

Narisada H, Aoki T, Sasaguri T, Hashimoto H, Konishi T et al (2006) Correlation between numeric gadolinium-enhanced dynamic MRI ratios and prognostic factors and histologic type of breast carcinoma. AJR Am J Roentgenol 187:297–306PubMedCrossRef

Teifke A, Behr O, Schmidt M, Victor A, Vomweg TW et al (2006) Dynamic MR imaging of breast lesions: correlation with microvessel distribution pattern and histologic characteristics of prognosis. Radiology 239:351–360PubMedCrossRef

Matsubayashi R, Matsuo Y, Edakuni G, Satoh T, Tokunaga O et al (2000) Breast masses with peripheral rim enhancement on dynamic contrast-enhanced MR images: correlation of MR findings with histologic features and expression of growth factors. Radiology 217:841–848PubMedCrossRef

Lee SH, Cho N, Kim SJ, Cha JH, Cho KS et al (2008) Correlation between high resolution dynamic MR features and prognostic factors in breast cancer. Korean J Radiol 9:10–18PubMedCentralPubMedCrossRef

Buadu LD, Murakami J, Murayama S, Hashiguchi N, Sakai S et al (1996) Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology 200:639–649PubMedCrossRef

10.

Buadu LD, Murakami J, Murayama S, Hashiguchi N, Sakai S et al (1997) Patterns of peripheral enhancement in breast masses: correlation of findings on contrast medium enhanced MRI with histologic features and tumor angiogenesis. J Comput Assist Tomogr 21:421–430PubMedCrossRef

11.

Elshof LE, Rutgers EJ, Deurloo EE, Loo CE, Wesseling J et al (2010) A practical approach to manage additional lesions at preoperative breast MRI in patients eligible for breast conserving therapy: results. Breast Cancer Res Treat 124:707–715PubMedCrossRef

12.

American College of Radiology (ACR) (2003) Breast imaging reporting and data system (BI-RADS Atlas). American College of Radiology, Reston, VA

13.

Deurloo EE, Tanis PJ, Gilhuijs KG, Muller SH, Kroger R et al (2003) Reduction in the number of sentinel lymph node procedures by preoperative ultrasonography of the axilla in breast cancer. Eur J Cancer 39:1068–1073PubMedCrossRef

14.

Egan RL (1982) Multicentric breast carcinomas: clinical-radiographic-pathologic whole organ studies and 10 year survival. Cancer 49:1123–1130PubMedCrossRef

15.

Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ et al (2008) Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 26:3153–3158PubMedCrossRef

16.

Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI et al (2007) Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25:2127–2132PubMedCrossRef

17.

Jiang L, Zhou Y, Wang Z, Lu X, Chen M et al (2013) Is there different correlation with prognostic factors between “non-mass” and “mass” type invasive ductal breast cancers? Eur J Radiol 82:1404–1409PubMedCrossRef

18.

Houssami N, Turner R, Macaskill P, Turnbull LW, McCready DR et al (2014) An individual person data meta-analysis of preoperative magnetic resonance imaging and breast cancer recurrence. J Clin Oncol 32:392–401PubMedCrossRef

19.

Pengel KE, Loo CE, Wesseling J, Pijnappel RM, Rutgers EJ et al (2014) Avoiding preoperative breast MRI when conventional imaging is sufficient to stage patients eligible for breast conserving therapy. Eur J Radiol 83:273–278PubMedCrossRef

20.

Hudis CA (2007) Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med 357:39–51PubMedCrossRef

21.

Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8:235–244PubMedCrossRef

22.

Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109:1721–1728PubMedCrossRef

23.

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434PubMedCrossRef

24.

Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275–1281PubMedCrossRef

25.

Colpaert CG, Vermeulen PB, Fox SB, Harris AL, Dirix LY et al (2003) The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. Breast Cancer Res Treat 81:137–147PubMedCrossRef

26.

Hasebe T, Tsuda H, Hirohashi S, Shimosato Y, Tsubono Y et al (1998) Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant histopathological prognostic parameter for predicting the long-term survival of the patients. Breast Cancer Res Treat 49:195–208PubMedCrossRef

27.

Colpaert C, Vermeulen P, van BP, Goovaerts G, Weyler J et al (2001) Intratumoral hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph node-negative breast cancer patients. Histopathology 39:416–425PubMedCrossRef

28.

Van den Eynden GG, Smid M, Van Laere SJ, Colpaert CG, Van dA I et al (2008) Gene expression profiles associated with the presence of a fibrotic focus and the growth pattern in lymph node-negative breast cancer. Clin Cancer Res 14:2944–2952PubMedCrossRef

29.

Carlson DJ, Keall PJ, Loo BW Jr, Chen ZJ, Brown JM (2011) Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia. Int J Radiat Oncol Biol Phys 79:1188–1195PubMedCentralPubMedCrossRef

30.

Ferrara N (2004) Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9(Suppl 1):2–10PubMedCrossRef

Titel: Association between rim enhancement of breast cancer on dynamic contrast-enhanced MRI and patient outcome: impact of subtype
verfasst von: Alexander M. Th. Schmitz
Claudette E. Loo
Jelle Wesseling
Ruud M. Pijnappel
Kenneth G. A. Gilhuijs
Publikationsdatum: 01.12.2014
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2014
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-014-3170-9

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Association between rim enhancement of breast cancer on dynamic contrast-enhanced MRI and patient outcome: impact of subtype

Abstract

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2014

Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers

Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy

The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis

Concerns about methods for determination of estrogens in body fluids

The frequency of the BLM*p.Q548X (c.1642C > T) mutation in breast cancer patients from Russia

Impact of histological subtype on long-term outcomes of neuroendocrine carcinoma of the breast

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie